When added to chemotherapy, researchers found no significant difference in overall or progression-free survival between PD-1 ...

Panelists discuss how private label agreements facilitate biosimilar market entry by allowing manufacturers to collaborate on ...

Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal ...

Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing ...

Susan Escudier, MD, FACP, explains some of the ways Texas Oncology mitigates financial toxicity and improve clinical trial access for underserved patients.

In this final interview clip, Michael A. Bernstein, MD, stresses the need for effective communication and proactive screening ...

Investigators from Shanghai, China, report responses above 90% by using levantinib and tislelizumab to treat patients with a ...

The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered ...

Michael A. Bernstein, MD, Stamford Health, addresses common misconceptions about tuberculosis amid the outbreak in Kansas ...

The Senate voted 52-48 to confirm Robert F. Kennedy Jr as secretary of HHS, setting up the vaccine skeptic to carry out major ...

The approach requires balance, however. There is the risk of increased AEs, as well as financial toxicity. Friedlander shared ...

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk ...